Jyoti Mayadev, MD
Enriched profileProfessor and Vice Chair of Developmental Therapeutics, Section Chief of Gynecologic Oncology, and Gynecologic Director of Brachytherapy, Department of Radiation Medicine and Applied Sciences, UC San Diego · University of California San Diego
Jyoti Mayadev is Professor and Vice Chair of Developmental Therapeutics, Section Chief of Gynecologic Oncology, and Gynecologic Director of Brachytherapy, Department of Radiation Medicine and Applied Sciences, UC San Diego at University of California San Diego. OpenAlex indexes 235 publications with 3,703 citations (h-index 32); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 27 Aug 2026
Jyoti Mayadev, M.D, is Professor and Vice Chair of Developmental Therapeutics, Section Chief of Gynecologic Oncology, and Gynecologic Director of Brachytherapy, Department of Radiation Medicine and Applied Sciences, UC San Diego at University of California San Diego, Department of Radiation Medicine and Applied Sciences / Moores Cancer Center. The public record shows 235 publications with 3,703 citations (h-index 32), centered on Endometrial and Cervical Cancer Treatments, Advanced Radiotherapy Techniques, Cervical Cancer and HPV Research. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2023–2025).
- Most recent indexed publication: 2025 · Nature communications
- Top research focus: Endometrial and Cervical Cancer Treatments
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 67.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
Sponsor: University of California, San Diego
- Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
Sponsor: Varian, a Siemens Healthineers Company
Industry payments
Updated 27 Aug 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20254 payments$15,360openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20253 payments
- Siemens Medical Solutions USA, Inc.Program year20254 payments
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Corticosteroid100%Mometasone Furoate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2023–2025 per NIH RePORTER. The latest:
- NCI Clinical Trial Research Strategy, Harnessing Innovation, and Implementation
University of California, San Diego
FY2025$173,920R50CA282102 - NCI Clinical Trial Research Strategy, Harnessing of Equity, and Implementation
University of California, San Diego
FY2024$173,920R50CA282102 - NCI Clinical Trial Research Strategy, Harnessing of Equity, and Implementation
University of California, San Diego
FY2023$173,920R50CA282102
Congress activity
Updated 27 Aug 2026
57 congress contributions (2005–2026) across ASCO, ASTRO per OpenAlex. The most recent:
- Bladder full or empty for pelvic radiation therapy (BEFORE): A multi-center randomized controlled trial.
ASCO Annual Meeting
ASCO2026Co-author - Tracking Changes in B Cell Antibodies in Cervical Cancer Patients Treated with Chemoradiation and Immunotherapy on GOG 9929
ASTRO Annual Meeting
ASTRO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.
Nature communications
Clinical Trial2025 - Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
Journal of clinical oncology
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice GuidelineArticle309 citations2020
- 03Global challenges of radiotherapy for the treatment of locally advanced cervical cancerArticle224 citations2022
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jyoti-mayadev-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Jyoti-Mayadev-58835103
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
amportal.astro.org/jyoti-mayadev-md-fastro-35192706
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗ - Apple Podcasts
podcasts.apple.com/nz/podcast/jyoti-s-mayadev-md-on-pembrolizumab-crt-fda-approval/id1522288886
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - X / Twitter
twitter.com/ASTRO_org/status/1821577294210556069
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →twitter.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →radonc.ucsd.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →radonc.ucsd.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →radonc.ucsd.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Editorial & leadership roles
journal and society appointments- Co-Chair
NRG Oncology Cervical Cancer Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗ - GYN Track Chair
ASTRO Scientific Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗ - Board Member
American Brachytherapy Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →radonc.ucsd.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →amportal.astro.org ↗
Media & interviews
press, podcasts and appearances- Guest
"Oncology On The Go" podcast (CancerNetwork), discussed pembrolizumab plus chemoradiotherapy FDA approval for locally advanced cervical cancer
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗ - Video interview
CancerNetwork, highlighted early- and late-onset toxicities from durvalumab/CRT in locally advanced cervical cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jay Giedd, MD
University of California San Diego
Robert Weinreb, MD
University of California San Diego
Dilip Jeste, MD
University of California San Diego
Igor Grant, MD
University of California San Diego